全球基因融合檢測市場
市場調查報告書
商品編碼
1895161

全球基因融合檢測市場

Global Gene Fusion Testing Market

出版日期: | 出版商: BCC Research | 英文 79 Pages | 訂單完成後即時交付

價格

本報告調查了全球基因融合檢測市場,並提供了市場概況、市場影響因素和市場機會分析、技術趨勢、市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析以及主要企業的概況。

目錄

第1章 執行摘要

  • 市場展望
  • 調查範圍
  • 市場概況
  • 概述
  • 當前市場情勢
  • 細分市場分析
  • 技術進步
  • 結論

第2章 市場概覽

  • 概述
  • 波特五力分析
  • 宏觀經濟因素分析
  • 醫療費用支出
  • 高齡化社會
  • 美國關稅情景

第3章 市場動態

  • 市場動態
  • 市場促進因素
  • 癌症發生率增加
  • 擴大個人化醫療的應用
  • 市場限制
  • 先進檢測方法高成本
  • 基因融合檢測的償付範圍複雜
  • 市場機會
  • 新興市場
  • 癌症意識和早期檢測計劃
  • 市場挑戰
  • 熟練專業人員短缺

第4章 新興科技與發展

  • 新興技術
  • 單分子長讀長定序
  • 基於 CRISPR 的融合檢測
  • 數位PCR(dPCR)和多重qPCR篩檢
  • AI

第5章 市場區隔分析

  • 細分市場分析
  • 市場分析:依技術分類
  • 重點總結
  • 次世代定序(NGS)
  • 聚合酵素鏈鎖反應(PCR)
  • 螢光原位雜合反應(FISH)
  • 免疫組織化學(IHC)
  • 市場分析:依適應症
  • 重點總結
  • 固態腫瘤
  • 血癌
  • 市場分析:依最終用戶
  • 重點總結
  • 製藥和生物技術公司
  • 醫院和診斷實驗室
  • 學術研究中心
  • 地理細分
  • 市場分析:依地區
  • 重點總結
  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 南美洲

第6章 競爭訊息

  • 重點總結
  • 競爭格局
  • 主要企業
  • 主要發展和策略

第7章 附錄

  • 調查方法
  • 來源
  • 簡稱
  • 公司簡介
  • AMOY DIAGNOSTICS CO. LTD.
  • BIOCARE MEDICAL LLC.
  • BIOCARTIS
  • F. HOFFMANN-LA ROCHE LTD.
  • GUARDANT HEALTH INC.
  • ILLUMINA INC.
  • INTEGRATED DNA TECHNOLOGIES INC.
  • MYRIAD GENETICS INC.
  • QIAGEN
  • THERMO FISHER SCIENTIFIC INC.
  • 新興Start-Ups/市場顛覆者
Product Code: HLC313A

This report provides detailed information on the global gene fusion testing market. It highlights current and future market trends, as well as a comprehensive competitive landscape. The report analyzes market trends with data from 2024, estimates from 2025, and projections of compound annual growth rates (CAGRs) through 2030.

Report Scope

The report provides an overview of the gene fusion testing market and analyzes market trends. It includes global revenue ($ million) using 2024 as the base year, estimated data for 2025 and projected data for 2026 through 2030.

The market is segmented by technology, indication and end user. By technology, the market is segmented into fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR) and immunohistochemistry (IHC). By indication, it is segmented into hematological cancer and solid tumor. By end user, the market comprises pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, as well as academic and research centers. Geographical regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America.

The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also discusses emerging technologies related to the market.

The report concludes by analyzing the competitive landscape and providing the leading gene fusion testing companies. It also contains a dedicated section of company profiles that covers details such as overview, key financials, product portfolio and recent developments in major companies.

Report Includes

  • Overview and an analysis of the global market for gene fusion testing technologies
  • Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
  • Understanding of the technology background for fusion genes, their applications in cancer research and long-read transcriptome sequencing data
  • Estimates of the current market size and revenue prospects, along with a corresponding market share analysis based on the technology type, disease indication, end user and region
  • Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations, prospects and the impact of macroeconomic factors
  • Insights derived from Porter's Five Forces model, as well as global supply chain analyses
  • Patent review, featuring key granted and published patents
  • Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
  • Profiles of the leading companies in the market

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary
  • Overview
  • Current Market Scenario
  • Segmental Analysis
  • Technological Advances
  • Conclusion

Chapter 2 Market Overview

  • Overview
  • Porter's Five Forces Analysis
  • Potential for New Entrants (Moderate)
  • Bargaining Power of Suppliers (Moderate to High)
  • Bargaining Power of Buyers (High)
  • Threat of Substitutes (Low)
  • Competition in the Industry (High)
  • Macroeconomic Factors Analysis
  • Healthcare Spending
  • Aging Population
  • U.S. Tariff Scenario

Chapter 3 Market Dynamics

  • Market Dynamics
  • Market Drivers
  • Increasing Incidence of Cancer
  • Rising Adoption of Personalized Medicine
  • Market Restraints
  • High Cost of Advanced Testing Method
  • Complex Reimbursement Coverage of Gene Fusion Testing
  • Market Opportunities
  • Emerging Markets
  • Increasing Awareness and Early Cancer Detection Programs
  • Market Challenges
  • Shortage of Skilled Professionals

Chapter 4 Emerging Technologies and Developments

  • Emerging Technologies
  • Single-Molecule Long-Read Sequencing
  • CRISPR-Based Fusion Detection
  • Digital PCR (dPCR) and Multiplex qPCR Assays
  • Artificial Intelligence (AI)

Chapter 5 Market Segmentation Analysis

  • Segmentation Breakdown
  • Market Analysis by Technology
  • Key Takeaways
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence in Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Market Analysis by Indication
  • Key Takeaways
  • Solid Tumor
  • Hematological Cancer
  • Market Analysis by End User
  • Key Takeaways
  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Diagnostic Laboratories
  • Academic and Research Centers
  • Geographic Breakdown
  • Market Analysis by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America

Chapter 6 Competitive Intelligence

  • Key Takeaways
  • Competitive Landscape
  • Leading Companies of Gene Fusion Testing Market
  • Key Developments and Strategies

Chapter 7 Appendix

  • Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • AMOY DIAGNOSTICS CO. LTD.
  • BIOCARE MEDICAL LLC.
  • BIOCARTIS
  • F. HOFFMANN-LA ROCHE LTD.
  • GUARDANT HEALTH INC.
  • ILLUMINA INC.
  • INTEGRATED DNA TECHNOLOGIES INC.
  • MYRIAD GENETICS INC.
  • QIAGEN
  • THERMO FISHER SCIENTIFIC INC.
  • Few Emerging Startups/Market Disruptors

List of Tables

  • Summary Table : Global Market for Gene Fusion Testing, by Region, Through 2030
  • Table 1 : Common Fusion Genes Identified Across Various Cancer Types
  • Table 2 : Gene Fusion Testing: Comparison of Various Technologies
  • Table 3 : Porter's Five Forces Analysis: Overview
  • Table 4 : Cancer Incidence, by Type, 2022
  • Table 5 : FDA-Approved Targeted Therapies for Gene Fusion-Driven Cancers
  • Table 6 : Gene Fusion Testing Cost, by Technology, 2024
  • Table 7 : Global Market for Gene Fusion Testing, by Technology, Through 2030
  • Table 8 : NGS in Gene Fusion: DNA versus RNA
  • Table 9 : PCR in Gene Fusion: Overview
  • Table 10 : FISH in Gene Fusion: Overview
  • Table 11 : IHC in Gene Fusion: Overview
  • Table 12 : Global Market for Gene Fusion Testing, by Indication, Through 2030
  • Table 13 : Gene Fusion-Targeted Therapies and FDA Companion Diagnostics
  • Table 14 : Hematological Gene Fusion Testing Products
  • Table 15 : Global Market for Gene Fusion Testing, by End User, Through 2030
  • Table 16 : Global Market for Gene Fusion Testing, by Region, Through 2030
  • Table 17 : North American Market for Gene Fusion Testing, by Technology, Through 2030
  • Table 18 : North American Market for Gene Fusion Testing, by Indication, Through 2030
  • Table 19 : North American Market for Gene Fusion Testing, by End User, Through 2030
  • Table 20 : European Market for Gene Fusion Testing, by Technology, Through 2030
  • Table 21 : European Market for Gene Fusion Testing, by Indication, Through 2030
  • Table 22 : European Market for Gene Fusion Testing, by End User, Through 2030
  • Table 23 : Asia-Pacific Market for Gene Fusion Testing, by Technology, Through 2030
  • Table 24 : Asia-Pacific Market for Gene Fusion Testing, by Indication, Through 2030
  • Table 25 : Asia-Pacific Market for Gene Fusion Testing, by End User, Through 2030
  • Table 26 : MEA Market for Gene Fusion Testing, by Technology, Through 2030
  • Table 27 : MEA Market for Gene Fusion Testing, by Indication, Through 2030
  • Table 28 : MEA Market for Gene Fusion Testing, by End User, Through 2030
  • Table 29 : South American Market for Gene Fusion Testing, by Technology, Through 2030
  • Table 30 : South American Market for Gene Fusion Testing, by Indication, Through 2030
  • Table 31 : South American Market for Gene Fusion Testing, by End User, Through 2030
  • Table 32 : Leading Provider of Gene Fusion Testing Market, 2024
  • Table 33 : Gene Fusion Testing: Recent Strategic Developments, 2023-2025
  • Table 34 : Report Information Sources
  • Table 35 : Abbreviations Used in the Gene Fusion Testing Market Report
  • Table 36 : Amoy Diagnostics Co. Ltd.: Company Snapshot
  • Table 37 : Amoy Diagnostics Co. Ltd.: Product Portfolio
  • Table 38 : Amoy Diagnostics Co. Ltd.: News/Key Developments, 2023-2025
  • Table 39 : Biocare Medical LLC.: Company Snapshot
  • Table 40 : Biocare Medical LLC.: Product Portfolio
  • Table 41 : Biocartis: Company Snapshot
  • Table 42 : Biocartis: Product Portfolio
  • Table 43 : F. Hoffmann-La Roche Ltd.: Company Snapshot
  • Table 44 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
  • Table 45 : F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Table 46 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
  • Table 47 : Guardant Health Inc.: Company Snapshot
  • Table 48 : Guardant Health Inc.: Financial Performance, FY 2023 and 2024
  • Table 49 : Guardant Health Inc.: Product Portfolio
  • Table 50 : Guardant Health Inc.: News/Key Developments, 2025
  • Table 51 : Illumina Inc.: Company Snapshot
  • Table 52 : Illumina Inc.: Financial Performance, FY 2023 and 2024
  • Table 53 : Illumina Inc.: Product Portfolio
  • Table 54 : Illumina Inc.: News/Key Developments, 2024
  • Table 55 : Integrated DNA Technologies Inc.: Company Snapshot
  • Table 56 : Integrated DNA Technologies Inc.: Product Portfolio
  • Table 57 : Integrated DNA Technologies Inc.: News/Key Developments, 2024
  • Table 58 : Myriad Genetics Inc.: Company Snapshot
  • Table 59 : Myriad Genetics Inc.: Financial Performance, FY 2023 and 2024
  • Table 60 : Myriad Genetics Inc.: Product Portfolio
  • Table 61 : QIAGEN: Company Snapshot
  • Table 62 : QIAGEN: Financial Performance, FY 2023 and 2024
  • Table 63 : QIAGEN: Product Portfolio
  • Table 64 : Thermo Fisher Scientific Inc.: Company Snapshot
  • Table 65 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
  • Table 66 : Thermo Fisher Scientific Inc.: Product Portfolio
  • Table 67 : List of a Few Emerging Startups/Market Disruptors

List of Figures

  • Summary Figure : Global Market Shares for Gene Fusion Testing, by Region, 2024
  • Figure 1 : Gene Fusion in Cancer
  • Figure 2 : Porter's Five Forces Analysis of the Gene Fusion Testing Market
  • Figure 3 : U.S. Major Expenditure, Projection and Trends, by Category, 2022-2033
  • Figure 4 : Gene Fusion Testing Market Dynamics
  • Figure 5 : Estimated Cancer Incidence Globally, Both Sexes, 2022-2050
  • Figure 6 : Emerging Trends/Technologies in the Gene Fusion Testing Market
  • Figure 7 : Global Market Shares for Gene Fusion Testing, by Technology, 2024
  • Figure 8 : Global Market Shares for Gene Fusion Testing, by Indication, 2024
  • Figure 9 : Global Market Shares for Gene Fusion Testing, by End User, 2024
  • Figure 10 : Global Market Shares for Gene Fusion Testing, by Region, 2024
  • Figure 11 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
  • Figure 12 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
  • Figure 13 : Guardant Health Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 14 : Guardant Health Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 15 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 16 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 17 : Myriad Genetics Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 18 : Myriad Genetics Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 19 : QIAGEN: Revenue Share, by Business Unit, FY 2024
  • Figure 20 : QIAGEN: Revenue Share, by Country/Region, FY 2024
  • Figure 21 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 22 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024